Drug Trial Radar · NCT03193398
BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
104
Actual
Start
Jun 12, 2017
Primary completion
Nov 12, 2018
Study completion Dec 12, 2018
Sponsor
- Lead sponsor
- BlackThorn Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 20, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will determine the efficacy, safety, and tolerability of a once-daily (QD) dose of up to 80 mg of BTRX-246040 for 8 weeks in participants with MDD.
Conditions
- Major Depressive Disorder
Interventions
BTRX-246040 oral capsule(s)Drug
BTRX-246040 administered once daily to patients with MDD for 8 weeks
Placebo oral capsule(s)Drug
administered once daily to patients with MDD for 8 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Investigator-administered MADRS Total Score From Baseline BTRX-246040 and PlaceboTime frame: Week 8
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
United States
Cerritos, California
United States
Garden Grove, California
United States, Florida
Jacksonville, Florida
United States
Lauderhill, Florida
United States, Florida
Orlando, Florida
United States
Libertyville, Illinois
United States
Rochester, New York
United States
Memphis, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.